YHB Investment Advisors Inc. Has $843,000 Position in Medtronic PLC (MDT)

YHB Investment Advisors Inc. lowered its position in shares of Medtronic PLC (NYSE:MDT) by 8.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,272 shares of the medical technology company’s stock after selling 832 shares during the period. YHB Investment Advisors Inc.’s holdings in Medtronic were worth $843,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Gideon Capital Advisors Inc. bought a new stake in shares of Medtronic during the third quarter valued at approximately $409,000. Clearstead Advisors LLC increased its position in shares of Medtronic by 5.5% during the third quarter. Clearstead Advisors LLC now owns 12,888 shares of the medical technology company’s stock valued at $1,268,000 after acquiring an additional 677 shares in the last quarter. Brightworth bought a new stake in shares of Medtronic during the third quarter valued at approximately $230,000. Alley Co LLC increased its position in shares of Medtronic by 2.9% during the third quarter. Alley Co LLC now owns 56,902 shares of the medical technology company’s stock valued at $5,597,000 after acquiring an additional 1,627 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its position in shares of Medtronic by 2.1% during the third quarter. Advisors Asset Management Inc. now owns 279,026 shares of the medical technology company’s stock valued at $27,448,000 after acquiring an additional 5,628 shares in the last quarter. 80.79% of the stock is owned by institutional investors.

In other Medtronic news, CEO Omar Ishrak acquired 12,000 shares of the business’s stock in a transaction dated Wednesday, January 9th. The stock was purchased at an average price of $84.05 per share, with a total value of $1,008,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Karen L. Parkhill acquired 3,000 shares of the business’s stock in a transaction dated Wednesday, January 9th. The shares were acquired at an average cost of $83.87 per share, with a total value of $251,610.00. The disclosure for this purchase can be found here. Insiders own 0.28% of the company’s stock.

NYSE:MDT opened at $84.84 on Friday. The company has a quick ratio of 2.11, a current ratio of 2.56 and a debt-to-equity ratio of 0.48. Medtronic PLC has a 12 month low of $76.41 and a 12 month high of $100.15. The company has a market capitalization of $113.22 billion, a price-to-earnings ratio of 17.79, a P/E/G ratio of 2.19 and a beta of 0.93.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 20th. The medical technology company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.15 by $0.07. Medtronic had a net margin of 7.44% and a return on equity of 13.51%. The business had revenue of $7.48 billion during the quarter, compared to the consensus estimate of $7.35 billion. During the same quarter in the previous year, the firm posted $1.07 EPS. The firm’s revenue was up 6.1% on a year-over-year basis. On average, sell-side analysts forecast that Medtronic PLC will post 5.13 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 18th. Stockholders of record on Friday, December 28th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date of this dividend is Thursday, December 27th. Medtronic’s payout ratio is 41.93%.

Several equities research analysts recently weighed in on the stock. Oppenheimer reissued a “buy” rating on shares of Medtronic in a research report on Friday, September 21st. Morgan Stanley raised their price target on shares of Medtronic from $98.00 to $102.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 2nd. Argus raised their price target on shares of Medtronic from $108.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, October 8th. Zacks Investment Research raised shares of Medtronic from a “hold” rating to a “buy” rating and set a $105.00 price target for the company in a research report on Tuesday, October 23rd. Finally, JPMorgan Chase & Co. raised shares of Medtronic from a “neutral” rating to an “overweight” rating and raised their price target for the company from $100.00 to $109.00 in a research report on Wednesday, December 19th. Nine investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Medtronic currently has an average rating of “Buy” and a consensus price target of $104.38.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thestockobserver.com/2019/01/12/yhb-investment-advisors-inc-has-843000-position-in-medtronic-plc-mdt.html.

Medtronic Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Further Reading: What is cost of equity?

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply